Set to support a previous Phase III trial ahead of authorisation applications, the new Chinese trial is set to examine the ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

Ziranu, P, Pretta, A, Aimola, V, Cau, F, Mariani, S, D'Agata, AP, Codipietro, C, Rizzo, D, Dell'Utri, V, Sanna, G, Moledda, G ...

TUESDAY, Nov. 26, 2024 (HealthDay News) -- Cisplatin is the go-to chemotherapy for people battling head-and-neck cancers, but ...

Pharmanovia has signed a licensing agreement with Lindis Biotech to commercialise catumaxomab, a new trifunctional ...

A type of immunotherapy appears to be effective in treating a deadly subset of thyroid cancer, according to the results of a ...

The accuracy of skin cancer diagnosis varied by lesion type, physician specialty and experience, and examination method, with ...

(RTTNews) - Sellas Life Sciences Group, Inc. (SLS), Wednesday announced positive data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective CDK9 inhibitor, ...

The proceeds will help Medicus Pharma advance its experimental non-invasive treatment for skin cancer. The second initial ...

随着精准医学发展，肿瘤中的驱动靶点不断被发现，针对这些靶点的靶向治疗也显著改善了患者预后。自 2004 年开始，MET 基因异常开始逐渐走入研究视野，然而其靶向治疗却一路曲折。历经数年研发，随着越来越多 MET 抑制剂的出现，MET ...

PET imaging using a radiolabeled antibody picked up clear cell renal cell carcinoma and could help avert unnecessary biopsies ...

SELLAS Life Sciences (SLS) announced data from preclinical studies identifying ASXL1 mutation as key predictor of SLS009, a highly selective ...